MAPT and Alzheimer disease: Interestingly, t-tau appears to be less accurate than 14-3-3 only in the differential diagnosis with AD; however, in cases where the differential diagnosis with AD is an issue, biomarker analysis can also take advantage of Aβ42 and p-tau and possibly total-PrP dosage, allowing for the calculation of t-tau/p-tau and other ratios based on different combinations of these four biomarkers, which have been reported to significantly improve diagnostic accuracy in such cases [1, 21, 67].